This Pharma Company Is Using Machine Learning And AI To Attempt To Transform Oncology Drug Development Processes

Comments
Loading...

Photo by National Cancer Institute on Unsplash

Panna Sharma, CEO and President of Lantern Pharma Inc. LTRN, was a guest speaker at Benzinga’s All Access on Jan. 28, 2022.

Panna discussed how Lantern Pharma is attempting to transform oncology drug development through data. Via AI and machine learning, the company has developed the means to harness data to optimize drug development processes - rescuing old drugs, relaunching them in the right settings, and developing new drugs and treatments.

Watch the full interview here:

LTRN Logo
LTRNLantern Pharma Inc
$4.0014.6%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum20.01
Growth-
Quality-
Value-
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: